{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:52:01Z","timestamp":1793379121804,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T00:00:00Z","timestamp":1526688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Bayer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s13318-018-0483-9","type":"journal-article","created":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T12:10:12Z","timestamp":1526731812000},"page":"715-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug\u2013Drug Interaction Studies In Vitro and In Vivo"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5428","authenticated-orcid":false,"given":"Roland","family":"Heinig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gerisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Nagelschmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Loewen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,19]]},"reference":[{"issue":"2","key":"483_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/hypertensionaha.114.04488","volume":"65","author":"J Bauersachs","year":"2015","unstructured":"Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65(2):257\u201363. \n                    https:\/\/doi.org\/10.1161\/hypertensionaha.114.04488\n                    \n                  .","journal-title":"Hypertension"},{"issue":"2","key":"483_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/j.ackd.2014.08.003","volume":"22","author":"MH Schwenk","year":"2015","unstructured":"Schwenk MH, Hirsch JS, Bomback AS. Aldosterone blockade in CKD: emphasis on pharmacology. Adv Chronic Kidney Dis. 2015;22(2):123\u201332. \n                    https:\/\/doi.org\/10.1053\/j.ackd.2014.08.003\n                    \n                  .","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"483_CR3","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/joe-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. 30\u00a0years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60\u00a0years of research and development. J Endocrinol. 2017;234(1):T125\u201340. \n                    https:\/\/doi.org\/10.1530\/joe-16-0600\n                    \n                  .","journal-title":"J Endocrinol"},{"key":"483_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271\u2013305. \n                    https:\/\/doi.org\/10.1007\/164_2016_76\n                    \n                  .","journal-title":"Handb Exp Pharmacol"},{"issue":"8","key":"483_CR5","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385\u2013403. \n                    https:\/\/doi.org\/10.1002\/cmdc.201200081\n                    \n                  .","journal-title":"ChemMedChem"},{"issue":"5","key":"483_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/mnh.0000000000000147","volume":"24","author":"P Kolkhof","year":"2015","unstructured":"Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015;24(5):417\u201324. \n                    https:\/\/doi.org\/10.1097\/mnh.0000000000000147\n                    \n                  .","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"483_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/fjc.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Barfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378. \n                    https:\/\/doi.org\/10.1097\/fjc.0000000000000091\n                    \n                  .","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"483_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","volume":"350","author":"P Kolkhof","year":"2012","unstructured":"Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol. 2012;350(2):310\u20137. \n                    https:\/\/doi.org\/10.1016\/j.mce.2011.06.025\n                    \n                  .","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"483_CR9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394. \n                    https:\/\/doi.org\/10.1001\/jama.2015.10081\n                    \n                  .","journal-title":"JAMA"},{"issue":"27","key":"483_CR10","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37(27):2105\u201314. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw132\n                    \n                  .","journal-title":"Eur Heart J"},{"issue":"31","key":"483_CR11","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/eht187\n                    \n                  .","journal-title":"Eur Heart J"},{"issue":"2","key":"483_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"S Lentini","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone\u2014results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30(2):172\u201384. \n                    https:\/\/doi.org\/10.1111\/fcp.12170\n                    \n                  .","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"483_CR13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment. Clin Pharmacol Drug Dev. 2016;5(6):488\u2013501. \n                    https:\/\/doi.org\/10.1002\/cpdd.263\n                    \n                  .","journal-title":"Clin Pharmacol Drug Dev"},{"key":"483_CR14","unstructured":"Gerisch M, Heinig R, Engelen A, Lang D, Kolkhof P, Platzek J et al. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans in vivo and in vitro. In preparation."},{"issue":"9","key":"483_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","volume":"94","author":"TA Jacobson","year":"2004","unstructured":"Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94(9):1140\u20136. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2004.07.080\n                    \n                  .","journal-title":"Am J Cardiol"},{"issue":"7","key":"483_CR16","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1124\/dmd.116.069542","volume":"44","author":"QJ Yang","year":"2016","unstructured":"Yang QJ, Fan J, Chen S, Liu L, Sun H, Pang KS. Metabolite kinetics: the segregated flow model for intestinal and whole body physiologically based pharmacokinetic modeling to describe intestinal and hepatic glucuronidation of morphine in rats in vivo. Drug Metab Dispos. 2016;44(7):1123\u201338. \n                    https:\/\/doi.org\/10.1124\/dmd.116.069542\n                    \n                  .","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"483_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2165\/00003088-200746080-00005","volume":"46","author":"Y Ohno","year":"2007","unstructured":"Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46(8):681\u201396. \n                    https:\/\/doi.org\/10.2165\/00003088-200746080-00005\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"483_CR18","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1208\/s12248-014-9663-y","volume":"16","author":"C Loue","year":"2014","unstructured":"Loue C, Tod M. Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data. AAPS J. 2014;16(6):1309\u201320. \n                    https:\/\/doi.org\/10.1208\/s12248-014-9663-y\n                    \n                  .","journal-title":"AAPS J"},{"issue":"7","key":"483_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1124\/dmd.110.032649","volume":"38","author":"M Gertz","year":"2010","unstructured":"Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010;38(7):1147\u201358. \n                    https:\/\/doi.org\/10.1124\/dmd.110.032649\n                    \n                  .","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"483_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1177\/0091270007302562","volume":"47","author":"T Okudaira","year":"2007","unstructured":"Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol. 2007;47(7):871\u20136. \n                    https:\/\/doi.org\/10.1177\/0091270007302562\n                    \n                  .","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"483_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1365-2125.1987.tb03226.x","volume":"24","author":"KK Hla","year":"1987","unstructured":"Hla KK, Henry JA, Latham AN. Pharmacokinetics and pharmacodynamics of two formulations of verapamil. Br J Clin Pharmacol. 1987;24(5):661\u20134.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"483_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/clpt.2011.313","volume":"91","author":"J Honkalammi","year":"2012","unstructured":"Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther. 2012;91(5):846\u201355. \n                    https:\/\/doi.org\/10.1038\/clpt.2011.313\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"483_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/clpt.2010.358","volume":"89","author":"J Honkalammi","year":"2011","unstructured":"Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther. 2011;89(4):579\u201386. \n                    https:\/\/doi.org\/10.1038\/clpt.2010.358\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"483_CR24","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/clpt.2011.295","volume":"91","author":"JS Floyd","year":"2012","unstructured":"Floyd JS, Kaspera R, Marciante KD, Weiss NS, Heckbert SR, Lumley T, et al. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin Pharmacol Ther. 2012;91(5):896\u2013904. \n                    https:\/\/doi.org\/10.1038\/clpt.2011.295\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"483_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/0091270004270642","volume":"45","author":"RL Walsky","year":"2005","unstructured":"Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005;45(1):68\u201378. \n                    https:\/\/doi.org\/10.1177\/0091270004270642\n                    \n                  .","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"483_CR26","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1124\/dmd.105.008672","volume":"34","author":"MF Paine","year":"2006","unstructured":"Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 \u201cpie\u201d. Drug Metab Dispos. 2006;34(5):880\u20136. \n                    https:\/\/doi.org\/10.1124\/dmd.105.008672\n                    \n                  .","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-018-0483-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0483-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0483-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T10:27:54Z","timestamp":1589884074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-018-0483-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,19]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["483"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0483-9","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,19]]},"assertion":[{"value":"19 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Research was funded by the sponsor, Bayer AG. Bayer AG agreed to the publication of the present data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RH, MG, AE and JN are employees of Bayer AG. SL is an employee of Chrestos Concept GmbH & Co. KG, which received funding for this analysis from Bayer AG. In addition, RH, MG, AE and JN have stock in Bayer AG, but are not paid in stock or stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all participants before study commencement.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}